Zealand Pharma A/S – NASDAQ:ZEAL
Zealand Pharma A/S stock price today
Zealand Pharma A/S stock price monthly change
Zealand Pharma A/S stock price quarterly change
Zealand Pharma A/S stock price yearly change
Zealand Pharma A/S key metrics
Market Cap | N/A |
Enterprise value | 434.49M |
P/E | -4.85 |
EV/Sales | 1.67 |
EV/EBITDA | -0.44 |
Price/Sales | 18.66 |
Price/Book | 6.83 |
PEG ratio | 0.24 |
EPS | -22.12 |
Revenue | 259.82M |
EBITDA | -976.48M |
Income | -957.00M |
Revenue Q/Q | -68.47% |
Revenue Y/Y | -33.15% |
Profit margin | -384.42% |
Oper. margin | -420.85% |
Gross margin | 62.29% |
EBIT margin | -420.85% |
EBITDA margin | -375.83% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZealand Pharma A/S stock price history
Zealand Pharma A/S stock forecast
Zealand Pharma A/S financial statements
| Jun 2021 | 84.32M | -296.81M | -351.99% |
|---|---|---|---|
| Sep 2021 | 54.01M | -280.26M | -518.86% |
| Sep 2021 | 106.40M | -198.88M | -186.91% |
| Mar 2022 | 15.07M | -181.04M | -1200.77% |
| 2021-11-11 | -1.13 | -0.73 |
|---|---|---|
| 2022-03-10 | -6.39 | -6.49 |
| 2022-05-12 | -6.61 | -5.16 |
| 2022-08-11 | -5.84 | -11.04 |
| Jun 2021 | 1924174000 | 537.43M | 27.93% |
|---|---|---|---|
| Sep 2021 | 2067629000 | 1.13B | 55.13% |
| Sep 2021 | 1660699000 | 474.95M | 28.6% |
| Mar 2022 | 1837382000 | 1.12B | 61.37% |
| Jun 2021 | -327.57M | 778K | 12.39M |
|---|---|---|---|
| Sep 2021 | -288.24M | -11.86M | 626.83M |
| Sep 2021 | -228.02M | -2.20M | -10.01M |
| Mar 2022 | -317.01M | 294.24M | -3.46M |
Zealand Pharma A/S alternative data
| Aug 2023 | 237 |
|---|---|
| Sep 2023 | 237 |
| Oct 2023 | 237 |
| Nov 2023 | 237 |
| Dec 2023 | 237 |
| Jan 2024 | 237 |
| Feb 2024 | 237 |
| Mar 2024 | 237 |
| Apr 2024 | 237 |
| May 2024 | 237 |
| Jun 2024 | 237 |
| Jul 2024 | 237 |
Zealand Pharma A/S other data
| Patent |
|---|
Application Filling date: 27 Sep 2019 Issue date: 25 Aug 2022 |
Application Filling date: 24 Feb 2022 Issue date: 11 Aug 2022 |
Application Filling date: 15 Jul 2020 Issue date: 4 Aug 2022 |
Grant Utility: Amylin analogues Filling date: 25 Oct 2019 Issue date: 12 Jul 2022 |
Application Filling date: 12 Jun 2020 Issue date: 30 Jun 2022 |
Grant Design: Medicament delivery device Filling date: 1 Jul 2020 Issue date: 21 Jun 2022 |
Application Filling date: 11 Feb 2022 Issue date: 26 May 2022 |
Grant Utility: Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease Filling date: 4 May 2018 Issue date: 10 May 2022 |
Grant Utility: KV1.3 blockers Filling date: 23 Jun 2021 Issue date: 5 Apr 2022 |
Grant Filling date: 10 May 2018 Issue date: 29 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 2 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA (1969) Chief Executive Officer & Pres | $1,890,000 |
Mr. Adam Sinding Steensberg M.D. (1974) Executive Vice President of R&D and Chief Medical Officer | $1,120,000 |
Mr. Matthew Donald Dallas (1975) Senior Vice President & Chief Financial Officer | $861,580 |
Ms. Hanne Heidenheim Bak (1953) Senior Project Director, R&D Operations Mang. and Employee Representative Director | $20,210 |
-
What's the price of Zealand Pharma A/S stock today?
One share of Zealand Pharma A/S stock can currently be purchased for approximately $17.59.
-
When is Zealand Pharma A/S's next earnings date?
Unfortunately, Zealand Pharma A/S's (ZEAL) next earnings date is currently unknown.
-
Does Zealand Pharma A/S pay dividends?
No, Zealand Pharma A/S does not pay dividends.
-
What is Zealand Pharma A/S's stock symbol?
Zealand Pharma A/S is traded on the NASDAQ under the ticker symbol "ZEAL".
-
What is Zealand Pharma A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Zealand Pharma A/S?
Shares of Zealand Pharma A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Zealand Pharma A/S's key executives?
Zealand Pharma A/S's management team includes the following people:
- Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA Chief Executive Officer & Pres(age: 56, pay: $1,890,000)
- Mr. Adam Sinding Steensberg M.D. Executive Vice President of R&D and Chief Medical Officer(age: 51, pay: $1,120,000)
- Mr. Matthew Donald Dallas Senior Vice President & Chief Financial Officer(age: 50, pay: $861,580)
- Ms. Hanne Heidenheim Bak Senior Project Director, R&D Operations Mang. and Employee Representative Director(age: 72, pay: $20,210)
-
How many employees does Zealand Pharma A/S have?
As Jul 2024, Zealand Pharma A/S employs 237 workers.
-
When Zealand Pharma A/S went public?
Zealand Pharma A/S is publicly traded company for more then 8 years since IPO on 9 Aug 2017.
-
What is Zealand Pharma A/S's official website?
The official website for Zealand Pharma A/S is zealandpharma.com.
-
How can i contact Zealand Pharma A/S?
Zealand Pharma A/S can be reached via phone at +45 88 77 36 00.
Zealand Pharma A/S company profile:
Zealand Pharma A/S
zealandpharma.comNASDAQ
237
Biotechnology
Healthcare
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Copenhagen, 2860
CIK: 0001674988
ISIN: US98920Y3045
CUSIP: 98920Y304
